AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Freedom Finance and Binance Join Forces in Digital Assets 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
MENLO PARK, Calif., May 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 8, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-239-9838 from the United States or 1-323-794-2551 internationally approximately 10 minutes before the start of the call. The passcode is 3450659.
A replay will be available through May 22, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 3450659.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
[email protected]
www.corcept.com
